Hayashi, Hidetoshi; Nadal, Ernest; Gray, Jhanelle E; Ardizzoni, Andrea; Caria, Nicola; Puri, Tarun; Grohe, Christian, Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations, «CLINICAL LUNG CANCER», 2022, 23, pp. 69 - 82 [articolo]
De Giglio, Andrea; Grandinetti, Valeria; Aprile, Marta; Borelli, Greta; Campus, Anita; Croci Chiocchini, Anna Laura; Busutti, Marco; Vischini, Gisella; Di Federico, Alessandro; Sperandi, Francesca; Melotti, Barbara; Ardizzoni, Andrea; La Manna, Gaetano; Gelsomino, Francesco, Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience, «LUNG CANCER», 2022, 174, pp. 91 - 96 [articolo]
Santoro, Armando; Su, Wu-Chou; Navarro, Alejandro; Simonelli, Matteo; Ch Yang, James; Ardizzoni, Andrea; Barlesi, Fabrice; Hyoung Kang, Jin; DiDominick, Sarah; Abdelhady, Ahmed; Chen, Xueying; Stammberger, Uz; Felip, Enriqueta, Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer, «LUNG CANCER», 2022, 166, pp. 170 - 177 [articolo]
Ricci A.D.; Rizzo A.; Mollica V.; Schiavina R.; Fiorentino M.; Brunocilla E.; Ardizzoni A.; Massari F., Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma: a change of paradigm? A meta-analysis of aggregate data, «ANTI-CANCER DRUGS», 2022, 33, pp. e61 - e68 [articolo]
Di Federico, Alessandro; De Giglio, Andrea; Gelsomino, Francesco; Sperandi, Francesca; Melotti, Barbara; Ardizzoni, Andrea, Predictors of Survival to Immunotherapy and Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis, «JOURNAL OF THE NATIONAL CANCER INSTITUTE», 2022, 10, pp. 29 - 42 [articolo]
Sisi, Monia; Fusaroli, Michele; De Giglio, Andrea; Facchinetti, Francesco; Ardizzoni, Andrea; Raschi, Emanuel; Gelsomino, Francesco, Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System, «TARGETED ONCOLOGY», 2022, 17, pp. 43 - 51 [articolo]Open Access
Pantaleo M.A.; Urbini M.; Schipani A.; Nannini M.; Indio V.; De Leo A.; Vincenzi B.; Brunello A.; Grignani G.; Casagrande M.; Fumagalli E.; Conca E.; Saponara M.; Gruppioni E.; Altimari A.; De Biase D.; Tallini G.; Ravegnini G.; Turchetti D.; Seri M.; Ardizzoni A.; Secchiero P.; Astolfi A., SDHA Germline Variants in Adult Patients With SDHA-Mutant Gastrointestinal Stromal Tumor, «FRONTIERS IN ONCOLOGY», 2022, 11, Article number: 778461, pp. 1 - 7 [articolo]Open Access
Raschi E.; Fusaroli M.; La Placa M.; Ardizzoni A.; Zamagni C.; Poluzzi E.; De Ponti F., Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System, «AMERICAN JOURNAL OF CLINICAL DERMATOLOGY», 2022, 23, pp. 247 - 255 [articolo]
Mazzeschi, Martina; Sgarzi, Michela; Romaniello, Donatella; Gelfo, Valerio; Cavallo, Carola; Ambrosi, Francesca; Morselli, Alessandra; Miano, Carmen; Laprovitera, Noemi; Girone, Cinzia; Ferracin, Manuela; Santi, Spartaco; Rihawi, Karim; Ardizzoni, Andrea; Fiorentino, Michelangelo; D'Uva, Gabriele; Győrffy, Balázs; Palmer, Ruth; Lauriola, Mattia, The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer, «JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH», 2022, 41, pp. 113 - 131 [articolo]Open Access
Raschi E.; Fusaroli M.; Massari F.; Mollica V.; Repaci A.; Ardizzoni A.; Poluzzi E.; Pagotto U.; Di Dalmazi G., The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System, «THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM», 2022, 107, pp. 3107 - 3114 [articolo]Open Access
De Giglio, Andrea; Tassinari, Elisa; Zappi, Arianna; Di Federico, Alessandro; Lenzi, Barbara; Sperandi, Francesca; Melotti, Barbara; Gelsomino, Francesco; Maltoni, Marco; Ardizzoni, Andrea, The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy, «CANCERS», 2022, 14, pp. 5845 - 5851 [articolo]Open Access
Nigro M.C.; Pirini M.G.; Garelli E.; Marchi M.; Musto A.; Pantaleo M.A.; Solli P.; Ardizzoni A.; Nannini M., Thoracic myopericytoma in an older adult, rare but possible: A case report, «THORACIC CANCER», 2022, 13, pp. 2532 - 2535 [articolo]Open Access
Di Federico A.; Filippini D.M.; Sperandi F.; Ardizzoni A.; Melotti B., Acute kidney injury as a possible immune-related adverse event associated with sustained complete response to BRAF and MEK inhibitors in advanced, V600E-mutated melanoma, «EUROPEAN JOURNAL OF CANCER», 2021, 147, pp. 58 - 59 [articolo]
Goss G.D.; Cobo M.; Lu S.; Syrigos K.; Lee K.H.; Goker E.; Georgoulias V.; Isla D.; Morabito A.; Min Y.J.; Ardizzoni A.; Bender S.; Cseh A.; Felip E., Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial, «ECLINICALMEDICINE», 2021, 37, Article number: 100940, pp. 1 - 9 [articolo]Open Access
Dall'Olio FG, Calabrò D, Conci N, Argalia G, Marchese PV, Fabbri F, Fragomeno B, Ricci D, Fanti S, Ambrosini V, Ardizzoni A., Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab., «EUROPEAN JOURNAL OF CANCER», 2021, 150, pp. 99 - 107 [articolo]
